These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma. Balch CM; Murray D; Presant C; Bartolucci AA Surgery; 1984 Apr; 95(4):454-9. PubMed ID: 6369594 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy or chemoimmunotherapy in the management of primary malignant melanoma of level III, IV, or V. Jacquillat C; Banzet P; Civatte J; Puissant A; Cottenot F; Israel L; Belaich S; Chastang C; Maral J Recent Results Cancer Res; 1978; 68():346-58. PubMed ID: 111323 [No Abstract] [Full Text] [Related]
6. High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. Thatcher D; Lind M; Morgenstern G; Carr T; Chadwick G; Jones R; Craig P Cancer; 1989 Apr; 63(7):1296-302. PubMed ID: 2646005 [TBL] [Abstract][Full Text] [Related]
7. Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years' follow-up. Carmo-Pereira J; Costa FO; Henriques E Cancer Treat Rep; 1984 Oct; 68(10):1211-4. PubMed ID: 6525593 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and vincristine with two dose schedules of 5-(3,3-dimethyl-1-triazino) imidazole 4-carboxamide (DTIC) in the treatment of disseminated malignant melanoma. Moon JH; Gailani S; Cooper MR; Hayes DM; Rege VB; Blom J; Falkson G; Maurice P; Brunner K; Glidewell O; Holland JF Cancer; 1975 Feb; 35(2):368-71. PubMed ID: 1111913 [TBL] [Abstract][Full Text] [Related]
9. The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma. Young DW; Lever RS; English JS; MacKie RM Cancer; 1985 May; 55(9):1879-81. PubMed ID: 2579722 [TBL] [Abstract][Full Text] [Related]
10. Adjuvant vemurafenib in resected, BRAF Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D; Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665 [TBL] [Abstract][Full Text] [Related]
11. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. Hauschild A; Weichenthal M; Balda BR; Becker JC; Wolff HH; Tilgen W; Schulte KW; Ring J; Schadendorf D; Lischner S; Burg G; Dummer R J Clin Oncol; 2003 Aug; 21(15):2883-8. PubMed ID: 12885805 [TBL] [Abstract][Full Text] [Related]
12. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. Veronesi U; Adamus J; Aubert C; Bajetta E; Beretta G; Bonadonna G; Bufalino R; Cascinelli N; Cocconi G; Durand J; De Marsillac J; Ikonopisov RL; Kiss B; Lejeune F; MacKie R; Madej G; Mulder H; Mechl Z; Milton GW; Morabito A; Peter H; Priario J; Paul E; Rumke P; Sertoli R; Tomin R N Engl J Med; 1982 Oct; 307(15):913-6. PubMed ID: 7050717 [TBL] [Abstract][Full Text] [Related]
13. A preliminary report of a pilot trial in adjuvant chemotherapy of primary melanoma. Kolarić K; Malenica B; Roth A Tumori; 1979 Apr; 65(2):229-36. PubMed ID: 462575 [TBL] [Abstract][Full Text] [Related]
14. [Adjuvant chemotherapy in the combined treatment of primary circumscribed malignant melanoma of the skin]. Korovin SI Lik Sprava; 1998 May; (3):114-7. PubMed ID: 9695586 [TBL] [Abstract][Full Text] [Related]
15. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma]. Kretschmer L; Helmbold P; Emmert S; Marsch WC Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468 [TBL] [Abstract][Full Text] [Related]
16. Chemotherapy of malignant melanoma with dimethyl traizeno imidazole carboxamide (DITC) and nitrosourea derivatives (BCNU, CCNU). Hill GJ; Ruess R; Berris R; Philpott GW; Parkin P Ann Surg; 1974 Aug; 180(2):167-74. PubMed ID: 4601984 [TBL] [Abstract][Full Text] [Related]
17. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma. McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662 [TBL] [Abstract][Full Text] [Related]
18. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. Pectasides D; Dafni U; Bafaloukos D; Skarlos D; Polyzos A; Tsoutsos D; Kalofonos H; Fountzilas G; Panagiotou P; Kokkalis G; Papadopoulos O; Castana O; Papadopoulos S; Stavrinidis E; Vourli G; Ioannovich J; Gogas H J Clin Oncol; 2009 Feb; 27(6):939-44. PubMed ID: 19139440 [TBL] [Abstract][Full Text] [Related]
19. [A combination chemotherapy of ACNU and DTIC for advanced malignant melanoma]. Domyo M; Ogawa M; Inagaki J; Horikoshi N; Ezaki K; Inoue K; Aiba K; Nagata T; Miyamoto H Gan To Kagaku Ryoho; 1982 May; 9(5):874-9. PubMed ID: 6964041 [TBL] [Abstract][Full Text] [Related]
20. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Verma S; Quirt I; McCready D; Bak K; Charette M; Iscoe N Cancer; 2006 Apr; 106(7):1431-42. PubMed ID: 16511841 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]